EHA 2020 European Hematology Association - June 11-14, 2020
Chronic Myeloid Leukemia - CML - 25th Congress of EHA
Frankfurt, Germany - Replaced by virtual
VIDEOS
*** coming soon***
*** coming soon***
CML PATIENT ASSOCIATIONS
EHA 2020 Congress: CML updates and tips to a virtual attendance
June 8. 2020, CML Advocates Network
EHA 2020 Congress: CML updates and tips to a virtual attendance
June 8. 2020, CML Advocates Network
NEWS
Asciminib Well-Tolerated, Active in Heavily Pretreated Ph+ CML
June 22, 2020, Oncology Learning Network
Low-Dose TKIs Before Therapy Cessation Leave Treatment-Free Remission Rates Unscathed in CML
June 15, 2020, Oncology Learning Network
Study Provides Support for TKI Discontinuation in Some Patients With CML
June 12, 2020, Cancer Therapy Advisor
Asciminib Well-Tolerated, Active in Heavily Pretreated Ph+ CML
June 22, 2020, Oncology Learning Network
Low-Dose TKIs Before Therapy Cessation Leave Treatment-Free Remission Rates Unscathed in CML
June 15, 2020, Oncology Learning Network
Study Provides Support for TKI Discontinuation in Some Patients With CML
June 12, 2020, Cancer Therapy Advisor
SOME INTERESTING ABSTRACTS FOR CML
*** TREATMENT FREE REMISSION. -- TKI DISCONTINUATION ***
CHARACTERIZATION OF PHENOTYPIC AND GENOTYPIC MARKERS AS PREDICTORS OF RELAPSE DURING TREATMENT-FREE REMISSION IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA
SECOND GENERATION TYROSINE KINASE INHIBITORS IN THE FIRST-LINE CAN REDUCE TIME TO TREATMENT-FREE REMISSION IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA
EFFICACY AND SAFETY OF NILOTINIB IN CHRONIC MYELOID LEUKEMIA PATIENTS WHO RELAPSED AFTER DISCONTINUATION OF IMATINIB FOR TREATMENT-FREE REMISSION: RESULTS OF THE FRENCH NILO POST-STIM STUDY
TARGETING DIPEPTIDYLPEPTIDASE IV (CD26) FOR A SECOND TKI DISCONTINUATION ATTEMPT IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA: DESIGN AND PHASE 1 RESULTS OF THE DOLPHIN-STAR STUDY.
LATE MOLECULAR RECURRENCES IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA EXPERIENCING TREATMENT FREE REMISSION.
HIGH LEVEL OF SUCCESSFUL TKI DISCONTINUATION OUTSIDE CLINICAL TRIALS - A POPULATION-BASED STUDY FROM THE SWEDISH CML REGISTRY
TARGETING DIPEPTIDYLPEPTIDASE IV (CD26) FOR A SECOND TKI DISCONTINUATION ATTEMPT IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA: DESIGN AND PHASE 1 RESULTS OF THE DOLPHIN-STAR STUDY
HLA POLYMORPHISMS PREDICT TREATMENT-FREE REMISSION FOLLOWING TKI DISCONTINUATION IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA
DOSE REDUCTION OF SECOND GENERATION TYROSINE KINASE INHIBITORS IN CHRONIC MYELOID LEUKEMIA PATIENTS WITH MAJOR AND DEEP MOLECULAR RESPONSE
*** TYROSINE KINASE INHIBITOR (TKI) ***
CHARACTERISTICS OF CML PATIENTS WITH PRIMARY AND SECONDARY FAILURE TO STANDARD DOSE OF IMATINIB IN THE FIRST LINE AND THEIR RESPONSE TO SECOND ТРЕАТМЕНТ LINE
DASATINIB INDUCES ENDOTHELIAL TO MESENCHYMAL TRANSITION IN HUMAN VASCULAR ENDOTHELIAL CELLS
DASATINIB PLUS PEG-INTERFERON ALPHA 2B COMBINATION IN NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA: 48-MONTHS RESULTS OF A PHASE 2 STUDY ON BEHALF OF THE FRENCH GROUP OF CML (FI-LMC)
MECHANISTIC INSIGHTS INTO THE INHIBITION OF T REGULATORY CELLS BY DASATINIB IN CML PATIENTS WITH CLONAL LYMPHOCYTOSIS
DOSE OPTIMIZATION OF SECOND-LINE BOSUTINIB IN ELDERLY CML PATIENTS: FINAL RESULTS OF THE BEST STUDY
BOSUTINIB FOR CHRONIC PHASE CHRONIC MYELOID LEUKEMIA AFTER IMATINIB FAILURE: ≥8-YEAR UPDATE OF A PHASE 1/2 STUDY
MOLECULAR RESPONSE BY 24 MONTHS OF NILOTINIB 300 MG BID TREATMENT IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CML) WHO FAILED TO ACHIEVE DMR WITH IMATINIB: RESULTS FROM THE ENESTPATH STUDY
SNPS IN ABC GENES CORRELATES WITH MOLECULAR RESPONSE IN CML PATIENTS TREATED WITH NILOTINIB
A PHASE 2 STUDY OF NILOTINIB (NIL) IN PEDIATRIC PATIENTS (PTS) WITH PHILADELPHIA CHROMOSOME–POSITIVE CHRONIC MYELOID LEUKEMIA (CML): ANALYSIS OF GROWTH AFTER ≥48 TREATMENT CYCLES
PONATINIB AT A LOWER DOSE IS A GOOD OPTION IN CHRONIC MYELOID LEUKEMIA (CML) PATIENTS INTOLERANT TO PREVIOUS TKIS
THE REAL–LIFE STUDY EVALUATING THE EFFICACY AND SAFETY OF PONATINIB 'TOPASE' REVEALS INDUCTION OF DEEP MOLECULAR RESPONSES IN A COHORT OF 75 TKI-RESISTANT OR INTOLERANT PATIENTS WITH CML
ASCIMINIB IN HEAVILY PRETREATED PATIENTS (PTS) WITH PHILADELPHIA CHROMOSOME–POSITIVE (PH+) CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) SENSITIVE TO TYROSINE KINASE INHIBITOR (TKI) THERAPY
*** CML STEM CELL SURVIVAL ***
IDENTIFICATION OF A DRUG-ABLE DOPAMINE RECEPTOR MEDIATED PATHWAY THAT IS CRITICAL FOR CML STEM CELL SURVIVAL
*** BCR-ABL1 TRANSCRIPTS ***
FAVORABLE OUTCOME IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA CO-EXPRESSING E13A2 AND E14A2 TRANSCRIPT TREATED FRONTLINE WITH NILOTINIB
BCR-ABL1 TRANSCRIPTS E13A2 AND E14A2 IN RELATION TO SURVIVAL AND MOLECULAR RESPONSES IN CML PATIENTS IN BOSNIA
CHRONIC MYELOID LEUKEMIA – SO MANY MUTATIONS, BUT BACK TO THE START
RARE BCR-ABL TRANSCRIPTS IN CML: E6A2 WITH EXTRAMEDULLARY LESIONS AND UNUSUAL E2A2 WITH PATIAL DELETION AND STIMULTANEOUS INSERTION (CASE REPORTS)
*** GENERAL ****
IN VITRO INVESTIGATION OF THE IMPACT OF BCR-ABL TYROSINE KINASE INHIBITORS ON ENDOTHELIAL CELLS
ENDOCRINE EFFECTS INDUCED BY TYROSINE KINASE INHIBITORS DURING THE TREATMENT OF CHRONIC MYELOID LEUKEMIA
EXPRESSION OF LEVEL MIR-17-92 GENES IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN DIFFERENT PHASES OF DISEASE
EVALUATION OF LABORATORY AND INSTRUMENTAL INDICATORS OF HEART FAILURE IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA UNDERGOING TREATMENT WITH TYROSINE KINASE INHIBITORS
THE APLICATIONS AND EFFICACY OF THERAPEUTIC PLATELETPHERESIS IN TWO PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS WITH EXTREME THROMBOCYTOSIS
INDUCTION AND MAINTENANCE FOR CHRONIC MYELOID LEUKEMIA -CHRONIC PHASE: A NOVEL TREATMENT STRATEGY
LONG-TERM FOLLOW UP OF CHRONIC MYELOGENOUS LEUKEMIA PATIENTS WITH CLONAL CHROMOSOMAL ABERRATIONS IN PHILADELPHIA NEGATIVE CELLS TREATED WITH TYROSINE KINASE INHIBITORS
MECHANISTIC AND THERAPEUTIC INSIGHTS INTO PRC2 REPROGRAMMING IN BLAST PHASE CML
SECONDARY MALIGNANCIES IN CHRONIC MYELOID LEUKEMIA : A SINGLE CENTER EXPERIENCE
THERAPEUTIC RESULTS OF SECOND GENERATION TKI IN THE TREATMENT OF CHRONIC MYELOID LEUKEMIA
LONG-TERM OUTCOMES OF TYROSINE KINASE INHIBITOR IN THIRD-LINE THERAPY OF CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS
HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA WHO DISCONTINUED TREATMENT
*** BY COUNTRIES***
NOVEL BCR-ABL1 KINASE DOMAIN MUTATIONS IN RUSSIAN PATIENTS RESISTANT TO ALL GENERATIONS OF TYROSINE KINASE INHIBITORS
DETERMINANTS OF FIRST-LINE THERAPY CHOICE IN CHRONIC PHASE CML: A REAL-LIFE SURVEY IN ITALY
THE EVOLUTION OF THE TREATMENT OF CHRONIC MYELOID LEUKEMIA: A NATIONWIDE POPULATION-BASED STUDY IN TAIWAN
THE IMPORTANCE OF MOLECULAR MONITORING CHRONIC MYELOID LEUKEMIA ( CML) PATIENTS ON MONTHS 3 AND 12 IN LOW INCOME-COUNTRIES LIKE ALBANIA
MAJOR MOLECULAR RESPONSE IS THE THRESHOLD FOR NGS ANALYSIS AND RESISTANT BCR-ABL1 MUTATION DETECTION IN CML
CHRONIC MYELOID LEUKEMIA: ABOUT 114 CASES - MAROCCO
LONG-TERM OUTCOMES OF TYROSINE KINASE INHIBITOR TREATMENT FOR CHRONIC MYELOID LEUKEMIA : A REAL WORLD DATA FROM MALAYSIA
DEMOGRAPHIC/CLINICAL FEATURES AND TREATMENT OUTCOMES OF CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS IN TURKEY: REAL-WORLD DATA
IMPACT OF INEQUITIES IN ACCESS IN THE RESPONSES TO TYROSINE KINASE INHIBITORS IN COLOMBIAN PATIENTS WITH CHRONIC MYELOID LEUKEMIA: FIRST RENEHOC REPORT ON CML
*** TREATMENT FREE REMISSION. -- TKI DISCONTINUATION ***
CHARACTERIZATION OF PHENOTYPIC AND GENOTYPIC MARKERS AS PREDICTORS OF RELAPSE DURING TREATMENT-FREE REMISSION IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA
SECOND GENERATION TYROSINE KINASE INHIBITORS IN THE FIRST-LINE CAN REDUCE TIME TO TREATMENT-FREE REMISSION IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA
EFFICACY AND SAFETY OF NILOTINIB IN CHRONIC MYELOID LEUKEMIA PATIENTS WHO RELAPSED AFTER DISCONTINUATION OF IMATINIB FOR TREATMENT-FREE REMISSION: RESULTS OF THE FRENCH NILO POST-STIM STUDY
TARGETING DIPEPTIDYLPEPTIDASE IV (CD26) FOR A SECOND TKI DISCONTINUATION ATTEMPT IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA: DESIGN AND PHASE 1 RESULTS OF THE DOLPHIN-STAR STUDY.
LATE MOLECULAR RECURRENCES IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA EXPERIENCING TREATMENT FREE REMISSION.
HIGH LEVEL OF SUCCESSFUL TKI DISCONTINUATION OUTSIDE CLINICAL TRIALS - A POPULATION-BASED STUDY FROM THE SWEDISH CML REGISTRY
TARGETING DIPEPTIDYLPEPTIDASE IV (CD26) FOR A SECOND TKI DISCONTINUATION ATTEMPT IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA: DESIGN AND PHASE 1 RESULTS OF THE DOLPHIN-STAR STUDY
HLA POLYMORPHISMS PREDICT TREATMENT-FREE REMISSION FOLLOWING TKI DISCONTINUATION IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA
DOSE REDUCTION OF SECOND GENERATION TYROSINE KINASE INHIBITORS IN CHRONIC MYELOID LEUKEMIA PATIENTS WITH MAJOR AND DEEP MOLECULAR RESPONSE
*** TYROSINE KINASE INHIBITOR (TKI) ***
CHARACTERISTICS OF CML PATIENTS WITH PRIMARY AND SECONDARY FAILURE TO STANDARD DOSE OF IMATINIB IN THE FIRST LINE AND THEIR RESPONSE TO SECOND ТРЕАТМЕНТ LINE
DASATINIB INDUCES ENDOTHELIAL TO MESENCHYMAL TRANSITION IN HUMAN VASCULAR ENDOTHELIAL CELLS
DASATINIB PLUS PEG-INTERFERON ALPHA 2B COMBINATION IN NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA: 48-MONTHS RESULTS OF A PHASE 2 STUDY ON BEHALF OF THE FRENCH GROUP OF CML (FI-LMC)
MECHANISTIC INSIGHTS INTO THE INHIBITION OF T REGULATORY CELLS BY DASATINIB IN CML PATIENTS WITH CLONAL LYMPHOCYTOSIS
DOSE OPTIMIZATION OF SECOND-LINE BOSUTINIB IN ELDERLY CML PATIENTS: FINAL RESULTS OF THE BEST STUDY
BOSUTINIB FOR CHRONIC PHASE CHRONIC MYELOID LEUKEMIA AFTER IMATINIB FAILURE: ≥8-YEAR UPDATE OF A PHASE 1/2 STUDY
MOLECULAR RESPONSE BY 24 MONTHS OF NILOTINIB 300 MG BID TREATMENT IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CML) WHO FAILED TO ACHIEVE DMR WITH IMATINIB: RESULTS FROM THE ENESTPATH STUDY
SNPS IN ABC GENES CORRELATES WITH MOLECULAR RESPONSE IN CML PATIENTS TREATED WITH NILOTINIB
A PHASE 2 STUDY OF NILOTINIB (NIL) IN PEDIATRIC PATIENTS (PTS) WITH PHILADELPHIA CHROMOSOME–POSITIVE CHRONIC MYELOID LEUKEMIA (CML): ANALYSIS OF GROWTH AFTER ≥48 TREATMENT CYCLES
PONATINIB AT A LOWER DOSE IS A GOOD OPTION IN CHRONIC MYELOID LEUKEMIA (CML) PATIENTS INTOLERANT TO PREVIOUS TKIS
THE REAL–LIFE STUDY EVALUATING THE EFFICACY AND SAFETY OF PONATINIB 'TOPASE' REVEALS INDUCTION OF DEEP MOLECULAR RESPONSES IN A COHORT OF 75 TKI-RESISTANT OR INTOLERANT PATIENTS WITH CML
ASCIMINIB IN HEAVILY PRETREATED PATIENTS (PTS) WITH PHILADELPHIA CHROMOSOME–POSITIVE (PH+) CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) SENSITIVE TO TYROSINE KINASE INHIBITOR (TKI) THERAPY
*** CML STEM CELL SURVIVAL ***
IDENTIFICATION OF A DRUG-ABLE DOPAMINE RECEPTOR MEDIATED PATHWAY THAT IS CRITICAL FOR CML STEM CELL SURVIVAL
*** BCR-ABL1 TRANSCRIPTS ***
FAVORABLE OUTCOME IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA CO-EXPRESSING E13A2 AND E14A2 TRANSCRIPT TREATED FRONTLINE WITH NILOTINIB
BCR-ABL1 TRANSCRIPTS E13A2 AND E14A2 IN RELATION TO SURVIVAL AND MOLECULAR RESPONSES IN CML PATIENTS IN BOSNIA
CHRONIC MYELOID LEUKEMIA – SO MANY MUTATIONS, BUT BACK TO THE START
RARE BCR-ABL TRANSCRIPTS IN CML: E6A2 WITH EXTRAMEDULLARY LESIONS AND UNUSUAL E2A2 WITH PATIAL DELETION AND STIMULTANEOUS INSERTION (CASE REPORTS)
*** GENERAL ****
IN VITRO INVESTIGATION OF THE IMPACT OF BCR-ABL TYROSINE KINASE INHIBITORS ON ENDOTHELIAL CELLS
ENDOCRINE EFFECTS INDUCED BY TYROSINE KINASE INHIBITORS DURING THE TREATMENT OF CHRONIC MYELOID LEUKEMIA
EXPRESSION OF LEVEL MIR-17-92 GENES IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN DIFFERENT PHASES OF DISEASE
EVALUATION OF LABORATORY AND INSTRUMENTAL INDICATORS OF HEART FAILURE IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA UNDERGOING TREATMENT WITH TYROSINE KINASE INHIBITORS
THE APLICATIONS AND EFFICACY OF THERAPEUTIC PLATELETPHERESIS IN TWO PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS WITH EXTREME THROMBOCYTOSIS
INDUCTION AND MAINTENANCE FOR CHRONIC MYELOID LEUKEMIA -CHRONIC PHASE: A NOVEL TREATMENT STRATEGY
LONG-TERM FOLLOW UP OF CHRONIC MYELOGENOUS LEUKEMIA PATIENTS WITH CLONAL CHROMOSOMAL ABERRATIONS IN PHILADELPHIA NEGATIVE CELLS TREATED WITH TYROSINE KINASE INHIBITORS
MECHANISTIC AND THERAPEUTIC INSIGHTS INTO PRC2 REPROGRAMMING IN BLAST PHASE CML
SECONDARY MALIGNANCIES IN CHRONIC MYELOID LEUKEMIA : A SINGLE CENTER EXPERIENCE
THERAPEUTIC RESULTS OF SECOND GENERATION TKI IN THE TREATMENT OF CHRONIC MYELOID LEUKEMIA
LONG-TERM OUTCOMES OF TYROSINE KINASE INHIBITOR IN THIRD-LINE THERAPY OF CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS
HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA WHO DISCONTINUED TREATMENT
*** BY COUNTRIES***
NOVEL BCR-ABL1 KINASE DOMAIN MUTATIONS IN RUSSIAN PATIENTS RESISTANT TO ALL GENERATIONS OF TYROSINE KINASE INHIBITORS
DETERMINANTS OF FIRST-LINE THERAPY CHOICE IN CHRONIC PHASE CML: A REAL-LIFE SURVEY IN ITALY
THE EVOLUTION OF THE TREATMENT OF CHRONIC MYELOID LEUKEMIA: A NATIONWIDE POPULATION-BASED STUDY IN TAIWAN
THE IMPORTANCE OF MOLECULAR MONITORING CHRONIC MYELOID LEUKEMIA ( CML) PATIENTS ON MONTHS 3 AND 12 IN LOW INCOME-COUNTRIES LIKE ALBANIA
MAJOR MOLECULAR RESPONSE IS THE THRESHOLD FOR NGS ANALYSIS AND RESISTANT BCR-ABL1 MUTATION DETECTION IN CML
CHRONIC MYELOID LEUKEMIA: ABOUT 114 CASES - MAROCCO
LONG-TERM OUTCOMES OF TYROSINE KINASE INHIBITOR TREATMENT FOR CHRONIC MYELOID LEUKEMIA : A REAL WORLD DATA FROM MALAYSIA
DEMOGRAPHIC/CLINICAL FEATURES AND TREATMENT OUTCOMES OF CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS IN TURKEY: REAL-WORLD DATA
IMPACT OF INEQUITIES IN ACCESS IN THE RESPONSES TO TYROSINE KINASE INHIBITORS IN COLOMBIAN PATIENTS WITH CHRONIC MYELOID LEUKEMIA: FIRST RENEHOC REPORT ON CML
